Filter Results:
(8)
Show Results For
- All HBS Web
(21)
- Faculty Publications (8)
Show Results For
- All HBS Web
(21)
- Faculty Publications (8)
Page 1 of 8
Results
- January 2017 (Revised October 2018)
- Case
Novartis: A Transformative Deal
By: David Collis and Ashley Hartman
When Joe Jimenez became CEO of Swiss-based Novartis in 2010, replacing longtime CEO Dan Vasella, he assumed control of one of the top pharmaceutical companies in the world. Vasella, an avowed advocate of diversification, had expanded the scope of the company and... View Details
Keywords: Novartis; GlaxoSmithKline; Asset Swap; Acquisitions; Divestiture; Strategy Alignment; Pharmaceuticals; Strategy; Business Strategy; Corporate Strategy; Diversification; Consolidation; Mergers and Acquisitions; Pharmaceutical Industry
Collis, David, and Ashley Hartman. "Novartis: A Transformative Deal." Harvard Business School Case 717-453, January 2017. (Revised October 2018.)
- May 2015 (Revised May 2017)
- Case
Colgate-Palmolive Company: Marketing Anti-Cavity Toothpaste
By: John A. Quelch and Margaret L. Rodriguez
In October 2013, Colgate-Palmolive Company, the world's leading oral care company, was about to launch its new Colgate® Maximum Cavity Protection™ plus Sugar Acid Neutralizer™ toothpaste in Brazil. Oral care category accounted for 46 percent of Colgate's $17.4 billion... View Details
Keywords: New Product Management; Consumer Segmentation; Global Marketing; Corporate Social Responsibility; Healthcare; Sustainability; Health Care and Treatment; Environmental Sustainability; Marketing; Segmentation; Product Development; Product Launch; Corporate Social Responsibility and Impact; Product Positioning; Consumer Products Industry; Brazil; United States
Quelch, John A., and Margaret L. Rodriguez. "Colgate-Palmolive Company: Marketing Anti-Cavity Toothpaste." Harvard Business School Case 515-050, May 2015. (Revised May 2017.)
- January 2014 (Revised January 2014)
- Supplement
GlaxoSmithKline in China (C)
By: John Quelch and Margaret L. Rodriguez
Keywords: China; Healthcare; Pharmaceutical Sales; Ethics; Multinational Firms and Management; Pharmaceutical Industry; China
Quelch, John, and Margaret L. Rodriguez. "GlaxoSmithKline in China (C)." Harvard Business School Supplement 514-092, January 2014. (Revised January 2014.) (This case is a follow up to GlaxoSmithKline (A), 514049 and GlaxoSmithKline (B), 514050.)
- November 2013
- Case
GlaxoSmithKline in China (A)
By: John A. Quelch and Margaret L. Rodriguez
Four GlaxoSmithKline employees were accused of bribing Chinese health care workers to prescribe the company's drugs. The accusations brought to light the questionable incentive structures of the Chinese health care system and the pressure on companies to adhere to... View Details
Keywords: Public Health; Pharmaceuticals; China; Bribery; CSR; Hong Bao; Health Care; Drug; GlaxoSmithKline; GSK; Witty; Government; Marketing; Health; Health Care and Treatment; Corporate Social Responsibility and Impact; Corporate Strategy; Corporate Governance; Business and Government Relations; Ethics; Pharmaceutical Industry; China; United Kingdom; United States
Quelch, John A., and Margaret L. Rodriguez. "GlaxoSmithKline in China (A)." Harvard Business School Case 514-049, November 2013.
- November 2013 (Revised January 2014)
- Teaching Note
GlaxoSmithKline In China (A), (B) and (C)
By: John A. Quelch
- November 2013 (Revised September 2015)
- Supplement
GlaxoSmithKline in China (B)
By: John A. Quelch and Margaret L. Rodriguez
In 2013, Chinese investigators detained four GSK employees for allegedly bribing health care staff to sell GSK pharmaceuticals. A month later, GSK's Asia Pacific regional president, Abbas Hussain, said the company would help identify corrupt practices. Two days later,... View Details
Keywords: Public Health; Pharmaceuticals; China; Bribery; CSR; Hong Bao; Health Care; Drug; GlaxoSmithKline; GSK; Witty; Government; Marketing; Health; Health Care and Treatment; Corporate Social Responsibility and Impact; Corporate Strategy; Corporate Governance; Business and Government Relations; Ethics; Pharmaceutical Industry; China; United Kingdom; United States
Quelch, John A., and Margaret L. Rodriguez. "GlaxoSmithKline in China (B)." Harvard Business School Supplement 514-050, November 2013. (Revised September 2015.)
- May 2005 (Revised April 2010)
- Case
GlaxoSmithKline: Reorganizing Drug Discovery (A)
By: Robert S. Huckman and Eli Strick
Describes the reorganization of drug discovery at GlaxoSmithKline (GSK) following the formation of GSK from the merger of Glaxo Wellcome and SmithKline Beecham. This reorganization placed nearly 2,000 research scientists into six centers of excellence in drug discovery... View Details
Keywords: Mergers and Acquisitions; Decision Choices and Conditions; Operations; Organizational Structure; Performance Improvement; Research and Development; Pharmaceutical Industry
Huckman, Robert S., and Eli Strick. "GlaxoSmithKline: Reorganizing Drug Discovery (A)." Harvard Business School Case 605-074, May 2005. (Revised April 2010.)
- May 2002 (Revised October 2005)
- Case
Marketing Antidepressants: Prozac and Paxil
By: Youngme E. Moon and Kerry Herman
Describes the marketing of Prozac and Paxil, two of the best-selling mental health drugs in history. Set in 2001, several months before the expiration of Prozac's patent, Eli Lilly (Prozac's manufacturer) and GlaxoSmithKline (Paxil's manufacturer) must decide how to... View Details
Keywords: Patents; Product Positioning; Competition; Ethics; Value; Health Care and Treatment; Brands and Branding; Pharmaceutical Industry; United States
Moon, Youngme E., and Kerry Herman. "Marketing Antidepressants: Prozac and Paxil." Harvard Business School Case 502-055, May 2002. (Revised October 2005.)